Mark Lee is a Nephrology physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11147 Washington Blvd
Whittier, CA 906063007
Telephone
562-695-6988Registry record last updated 20 Jul 2012.
Clinical trials
- Locking Plates for Distal Femur Fractures - a Multicenter Case Review
Sponsor: AO Innovation Translation Center
- Is Univalving or Bivalving of Long Arm Casts for Forearm Fractures Necessary?
Sponsor: Connecticut Children's Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ardelyx, Inc.Program year202514 payments
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
- AKEBIA THERAPEUTICS INCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
37.7%Calcium channel blocker9.4%Amlodipine Besylate69%Nifedipine Er31%Part D≥59 patientsBeta blocker6.1%Carvedilol37%Metoprolol Tartrate30%Labetalol Hcl17%Metoprolol Succinate10%Nebivolol Hcl7%Part D<11 patients+ 10 more classes in this area
Metabolism & gastrointestinal
18.2%SGLT2 inhibitor6.2%Farxiga76%Dapagliflozin18%Jardiance6%Part D<11 patientsProton pump inhibitor3.8%Omeprazole44%Pantoprazole Sodium41%Esomeprazole Magnesium15%Part D<11 patients+ 10 more classes in this area
Other
17.1%Drugs for treatment of hyperkalemia and hyperphosphatemia9.9%Velphoro64%Auryxia15%Lokelma13%Lanthanum Carbonate8%Part D<11 patientsPhosphate Binder7.3%Sevelamer Carbonate86%Sevelamer Hcl14%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”